Pharvaris (NASDAQ:PHVS) Trading 9.9% Higher - What's Next?

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) shot up 9.9% during mid-day trading on Friday . The stock traded as high as $21.20 and last traded at $21.78. 34,633 shares were traded during trading, a decline of 51% from the average session volume of 70,739 shares. The stock had previously closed at $19.83.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PHVS. Wedbush restated an "outperform" rating and issued a $27.00 price objective on shares of Pharvaris in a report on Thursday, June 5th. Guggenheim assumed coverage on Pharvaris in a research note on Wednesday, June 11th. They set a "buy" rating and a $32.00 price objective on the stock. Finally, Cantor Fitzgerald lowered their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $36.20.

Pharvaris Trading Up 26.7%

The firm has a fifty day simple moving average of $17.26 and a two-hundred day simple moving average of $16.71. The firm has a market cap of $1.31 billion, a PE ratio of -8.35 and a beta of -2.82.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.09). Equities analysts expect that Pharvaris N.V. will post -2.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in shares of Pharvaris during the fourth quarter valued at $111,000. JPMorgan Chase & Co. raised its holdings in Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after acquiring an additional 2,847 shares during the last quarter. Geode Capital Management LLC lifted its position in Pharvaris by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock valued at $735,000 after acquiring an additional 1,356 shares in the last quarter. FMR LLC boosted its stake in Pharvaris by 3.6% during the 4th quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after purchasing an additional 189,714 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Pharvaris by 11.2% in the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after purchasing an additional 994 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.